Wyvern Pharmaceuticals Inc.
$50,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2018-2019
Canada
The ability of Wyvern DR to down regulate or reduce the expression of multiple checkpoint molecules in human lung epithelium will be investigated.